Illumina
Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.
Illumina Company Profile
President & CEO: Francis deSouza
CEO photo:
Website: www.illumina.com
Ticker symbol: ILMN
Headquarters: San Diego, CA
Illumina employees: 5,500+ globally
Revenues: $2.4 Billion USD in 2016
Founded: 1998
Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel
Illumina News
Illumina to Incorporate Myriad's Genomic Instability Score Into Updated TSO 500 Cancer Assay
GIS measures DNA repair defects via loss of heterozygosity, large-scale state transition, and telomere allele imbalance.
Cancer Study Sees Tailored Treatment, Outcome Boost with Comprehensive Genomic Profiling
Investigators tracked clinical and treatment outcomes for advanced cancer patients who had tumor testing with an in-house assay developed by Providence Health.
In Brief This Week: Genomate Health, Aspira Women’s Health, U of Adelaide, Illumina, Asklepios
News items for the week of Nov. 4, 2024.
FDA Approves Illumina Cancer Genomic Profiling Assay as CDx for Kinase Inhibitors From Bayer, Lilly
The test's first CDx approvals are for Bayer's Vitrakvi in solid tumors and for Lilly's Retevmo in non-small cell lung cancer.
German Precision Medicine Model Project Gets Ready for Kickoff as Commercial Providers Cry Foul
The €700 million project will pilot diagnostic genomic testing for cancer and rare diseases for at least five years, but private labs cannot participate.